Expression and clinical implication of long intragenic non-coding RNA-p21 and glucose transporter 1 in primary hepatocellular carcinoma
Expression and clinical implication of long intragenic non-coding RNA-p21 and glucose transporter 1 in primary hepatocellular carcinoma
复制标题
长基因内非编码RNA-p21和葡萄糖转运蛋白1在原发性肝细胞癌中的表达及临床意义
DOI：
--
复制
发表时间：
--
影响因子：
0.1
通讯作者：
Jianhong Zhong
中科院分区：
文献类型：
--
作者：
Yingyang Liao;Hao Huang;Jingrong He;Jindu Li;Hang Ye;Ningfu Peng;Jianhong Zhong
探讨长基因内非编码RNA-p21(lincRNA-p21)和葡萄糖转运蛋白1(GLUT-1)在原发性肝细胞癌中的表达及其临床意义。方法：对264例肝细胞癌患者的临床资料进行回顾性研究，检测lincRNA-p21和GLUT-1mRNA在肝细胞癌及癌旁正常组织中的相对表达，并对GLUT-1进行定性分析。结果：肝细胞癌组织中lincRNA-p21的相对表达低于癌旁正常组织，而GLUT-1的阳性表达率和GLUT-1miRNA的相对表达高于癌旁正常组织(均P<0.001)。随着肿瘤体积的增大，甲胎蛋白(AFP)值升高，T分期增高，远处转移和分化程度变差，GLUT-1mRNA的相对表达增加，而RNA-p21的相对表达降低(均P<0.05)。GLUT-1阴性患者的中位生存期长于GLUT-1阳性患者(29个月，95%CI：27.659~30.341 vs 25个月，95%CI：24.133~25.867)，差异有统计学意义(χ2=30.950，P<；0.001)，GLUT-1阳性患者lincRNA-p21相对表达低于GLUT-1阴性患者，差异有统计学意义(P<；0.05)。LincRNA-p21的相对表达与GLUT-1miRNA呈负相关(r=-0.256，P=0.017)。结论：lincRNA-p21和GLUT-1在肝细胞癌的发生发展中起重要作用。LincRNA-p21降低而GLUT-1升高提示预后不良，可作为判断肝癌恶性程度和预后的潜在生物标志物。
To explore the expression of long intragenic non-coding RNA-p21 (lincRNA-p21) and glucose transporter 1 (Glut-1) in primary hepatocellular carcinoma (HCC) and their clinical values. Methods: A retrospective study was collected from 264 HCC patients; the relative expression of lincRNA-p21 and Glut-1 mRNA in HCC and adjacent normal tissues were measured, and a qualitative analysis was made for Glut-1. Results: The relative expression of lincRNA-p21 in HCC tissues was lower than those in adjacent normal tissues, but the positive rate of Glut-1 and the relative expression of Glut-1 miRNA were higher (all P<0.001). With the increase in the size of HCC tumors, the alpha fetoprotein (AFP) values became higher, T stages got higher, distant metastasis and differentiation of lymph nodes got poorer, the relative expression of Glut-1 mRNA increased, but the relative expression of RNA-p21 decreased (all P<0.05). The median survival time in Glut-1 negative patients was longer than Glut-1 positive patients (29 months, 95% CI: 27.659-30.341 vs 25 months, 95% CI: 24.133-25.867), and they were significantly different (χ2=30.950, P<0.001); the relative expression of lincRNA-p21 was lower in Glut-1 positive patients than Glut-1 negative ones, and the differences were significant (P<0.05). The relative expression of lincRNA-p21 was negatively correlated to Glut-1 miRNA (r=-0.256, P=0.017). Conclusion: LincRNA-p21 and Glut-1 play the crucial role in occurrence and development of HCC. Decreased lincRNA-p21 but elevated Glut-1 suggest poor prognosis, and they can be used as potential biomarkers for judging the malignancy and prognosis of HCC